Imviva Biotech wins FDA IND clearance for dual-target allogeneic CAR-T
Imviva Biotech has received FDA clearance for an Investigational New Drug application for CTA313, its dual-targeting CD19/BCMA allogeneic CAR-T cell therapy for B-cell-mediated autoimmune diseases. The Boston-based company said the clearance allows it to initiate a Phase 1b basket study evaluating safety, efficacy, and cellular pharmacokinetics across systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis.
CTA313 is derived from healthy donor cells and is engineered using Imviva's proprietary ANSWER™ platform, which incorporates inhibitory ligands and genetic edits designed to resist host immune rejection and maintain therapeutic durability. The off-the-shelf format means the product can be manufactured in advance and stored, sidestepping the apheresis process required for autologous CAR-T therapies — a logistical and clinical advantage the company says could be particularly meaningful for patients with rapidly progressing disease.
The therapy and its basket design
The FDA-cleared Phase 1b design uses a basket structure, evaluating CTA313 simultaneously across multiple autoimmune indications rather than pursuing separate trials for each. This approach, increasingly favoured by regulators and sponsors in oncology, is less established in autoimmune disease but allows promising signals to be carried forward into Phase 2 development efficiently.
Chief Medical Officer Jan Davidson-Moncada said the clearance validates "not only CTA313 as a therapeutic candidate, but the broader versatility of our ANSWER™ platform technology." The company said CTA313 has already been evaluated in an open-label Phase 1/2 study across multiple autoimmune conditions in China, covering renal, rheumatologic, endocrine, gastrointestinal, haematological, and neurological indications — though no data from that study were included in the announcement.
Imviva also noted a prior FDA interaction: an IND clearance for CD7-targeted therapy CTD402 in T-cell malignancies was granted in February 2025, followed by an orphan drug designation for that programme in January 2026. The company characterised the new clearance as evidence of growing regulatory confidence in its allogeneic platform.
Market context and competitive landscape
The use of CAR-T cell therapy in autoimmune disease has attracted significant attention over the past two years, following published case series from academic centres — most prominently at the University of Erlangen-Nuremberg — showing durable remissions in patients with refractory lupus and other conditions. Several clinical-stage companies are pursuing similar allogeneic approaches, including Catamaran Bio, Carcell Therapeutics, and a number of China-originated programmes seeking global regulatory footing. Autologous CAR-T programmes in autoimmune disease are also advancing, led by Kyverna Therapeutics, which received FDA Breakthrough Therapy designation for its KYV-101 programme.
Imviva's dual CD19/BCMA targeting differentiates CTA313 from single-target approaches: CD19 has established relevance in B-cell depletion, while BCMA addresses long-lived plasma cells that can sustain autoantibody production even after CD19-directed therapies. Whether dual targeting translates into superior clinical durability remains to be demonstrated in the Phase 1b trial.
The broader competitive question is manufacturing scale and cost. Allogeneic therapies carry an inherent promise of reduced per-patient cost relative to bespoke autologous manufacturing, but few allogeneic CAR-T programmes have yet demonstrated the consistency required for commercial viability at scale. Investors and clinicians will be watching the Phase 1b safety readout closely, particularly for signals of graft-versus-host activity and persistence of the allogeneic cells in an immunologically active host.